Related Experiment Video
Updated: Aug 18, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
[Bone loss in men under androgen-deprivation therapy for prostate cancer]
Kazuhiro Ishizaka1, Tatsuya Machida, Ken-Ichiro Yoshida
1Department of Urology, Kanto Central Hospital.
Abstract:
Bone is a major target tissue for sex hormones and hypogonadism is a known cause of male osteoporosis. Androgen-deprivation therapy (ADT) for prostate cancer yields hypogonadotropic status and accelerates age-related decrease in bone mineral density. The risk for osteoporotic fractures is also increased which may lead to a shorter life expectancy for prostatic cancer patients. Baseline and follow up bone density measurement is desired for all men beginning ADT and it is advisable to take calcium and vitamin D as well as maintain a moderate exercise. Bisphosphonate is a possible treatment for those in whom osteoporosis develops. More data are desirable to make a guideline to prevent and treat male osteoporosis under ADT.
Insights
Androgen-deprivation therapy (ADT) for prostate cancer can lead to male osteoporosis and increase fracture risk. Regular bone density monitoring, calcium, vitamin D, exercise, and potentially bisphosphonates are recommended for affected patients.
Area of Science:
- Endocrinology
- Oncology
- Bone Metabolism
Context:
- Bone is a key target for sex hormones.
- Hypogonadism is a significant cause of male osteoporosis.
- Androgen-deprivation therapy (ADT) for prostate cancer induces hypogonadism.
Purpose:
- To highlight the impact of ADT on bone health in prostate cancer patients.
- To discuss the risks of osteoporosis and fractures associated with ADT.
- To suggest preventative and therapeutic strategies for ADT-induced bone loss.
Summary:
- ADT accelerates age-related bone mineral density loss.
- Increased risk of osteoporotic fractures is observed in patients on ADT.
- Recommendations include baseline and follow-up bone density measurements, calcium/vitamin D supplementation, moderate exercise, and bisphosphonate therapy if osteoporosis develops.
Impact:
- Informs clinical practice regarding bone health management in prostate cancer patients undergoing ADT.
- Emphasizes the need for proactive bone density monitoring and intervention.
- Highlights the potential to improve life expectancy for prostate cancer patients by mitigating osteoporosis-related complications.
Related Concept Videos
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Bone Remodeling
The Effect of Aging on Tissues
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
